Bayer must face US company's flea and tick drug antitrust lawsuit [Reuters]
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Reuters
for rival tick and flea treatments, according to a ruling unsealed on Wednesday. U.S. District Judge Beth Freeman in San Jose, California, the plaintiff, pet products company Tevra, provided sufficient evidence for a jury to hear claims that Bayer schemed with retailers and distributors to block Tevra's generic, lower-cost tick and flea pet medication. Bayer has denied any wrongdoing. It deferred a request for comment on Wednesday to Elanco Animal Health , which the company's animal health business five years ago in a $7.6 billion deal. Elanco, which is not a defendant, had no immediate comment on the ruling on Wednesday. Tevra did not immediately respond to a request for comment, and a lawyer for the company had no immediate comment. In a partial win for Bayer, Freeman said the plaintiffs could not pursue damages after July 31, 2020, when Bayer exited the animal health market. A trial in the case is scheduled for July. Americans spend billions of dollars a year on tick an
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics [Yahoo! Finance]Yahoo! Finance
- Study Design and Baseline Characteristics of Prespecified, Exploratory Pooled Analysis to Investigate Effect of Finerenone on Cardio-Kidney Outcomes in Patients with CKD and Type 2 Diabetes and/or Heart Failure Shared at Heart Failure 2024 Congress [YahooYahoo
- Bayer to Present Investigational Data from Comprehensive KERENDIA® (finerenone) Clinical Trial Program at Heart Failure 2024 Congress [Yahoo! Finance]Yahoo! Finance
- AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- Monsanto Wins Appeal Ruling in Erickson v. Monsanto [Yahoo! Finance]Yahoo! Finance